Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom.
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom.
Mov Disord. 2020 Oct;35(10):1834-1842. doi: 10.1002/mds.28188. Epub 2020 Jul 11.
Synaptic loss is a prominent and early feature of many neurodegenerative diseases.
We tested the hypothesis that synaptic density is reduced in the primary tauopathies of progressive supranuclear palsy (PSP) (Richardson's syndrome) and amyloid-negative corticobasal syndrome (CBS).
Forty-four participants (15 CBS, 14 PSP, and 15 age-/sex-/education-matched controls) underwent PET with the radioligand [ C]UCB-J, which binds to synaptic vesicle glycoprotein 2A, a marker of synaptic density; participants also had 3 Tesla MRI and clinical and neuropsychological assessment.
Nine CBS patients had negative amyloid biomarkers determined by [ C]PiB PET and hence were deemed likely to have corticobasal degeneration (CBD). Patients with PSP-Richardson's syndrome and amyloid-negative CBS were impaired in executive, memory, and visuospatial tasks. [ C]UCB-J binding was reduced across frontal, temporal, parietal, and occipital lobes, cingulate, hippocampus, insula, amygdala, and subcortical structures in both PSP and CBD patients compared to controls (P < 0.01), with median reductions up to 50%, consistent with postmortem data. Reductions of 20% to 30% were widespread even in areas of the brain with minimal atrophy. There was a negative correlation between global [ C]UCB-J binding and the PSP and CBD rating scales (R = -0.61, P < 0.002; R = -0.72, P < 0.001, respectively) and a positive correlation with the revised Addenbrooke's Cognitive Examination (R = 0.52; P = 0.01).
We confirm severe synaptic loss in PSP and CBD in proportion to disease severity, providing critical insight into the pathophysiology of primary degenerative tauopathies. [ C]UCB-J may facilitate treatment strategies for disease-modification, synaptic maintenance, or restoration. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
突触损失是许多神经退行性疾病的一个突出和早期特征。
我们检验了突触密度在原发性 tau 病(进行性核上性麻痹(PSP)(Richardson 综合征)和淀粉样阴性皮质基底节综合征(CBS)中降低的假说。
44 名参与者(15 名 CBS、14 名 PSP 和 15 名年龄/性别/教育匹配的对照组)接受了放射性配体 [C]UCB-J 的 PET 检查,该配体与突触囊泡糖蛋白 2A 结合,突触囊泡糖蛋白 2A 是突触密度的标志物;参与者还进行了 3T MRI 以及临床和神经心理学评估。
9 名 CBS 患者的淀粉样生物标志物[C]PiB PET 为阴性,因此被认为可能患有皮质基底节变性(CBD)。PSP-Richardson 综合征和淀粉样阴性 CBS 患者在执行、记忆和视空间任务中受损。与对照组相比,PSP 和 CBD 患者的额、颞、顶、枕叶、扣带回、海马、岛叶、杏仁核和皮质下结构的 [C]UCB-J 结合均减少(P < 0.01),中位数减少高达 50%,与尸检数据一致。即使在脑萎缩最小的区域,也广泛存在 20%至 30%的减少。全局 [C]UCB-J 结合与 PSP 和 CBD 评分量表呈负相关(R = -0.61,P < 0.002;R = -0.72,P < 0.001),与改良 Addenbrooke 认知评估呈正相关(R = 0.52;P = 0.01)。
我们证实了 PSP 和 CBD 中严重的突触丢失与疾病严重程度成正比,为原发性退行性 tau 病的病理生理学提供了重要的见解。[C]UCB-J 可能有助于疾病修饰、突触维持或恢复的治疗策略。© 2020 作者。运动障碍由 Wiley 期刊公司代表国际帕金森病和运动障碍协会出版。